Variant ATTR-CM Responds Powerfully to Acoramidis Therapy

11 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this CardioNerds episode, Anna Radakrishnan, MD, MBA — CardioNerds Fellow, The Mount Sinai Hospital — and Georgia Vasilakis Tsatiris, MD — CardioNerds Fellow, University of Pittsburgh Medical Center — interview Kevin Alexander, MD, FACC, FHFSA — Assistant Professor of Cardiovascular Medicine, Stanford Health Care about groundbreaking new JAMA Cardiology and AHA 2025 data from ATTRibute-CM. This fresh genotype-focused analysis reveals that acoramidis significantly reduces mortality and first cardiovascular hospitalization in both wild-type and variant ATTR cardiomyopathy, with variant carriers — including those with the common V142I variant among individuals of West African ancestry — experiencing a nearly 60% risk reduction. The discussion highlights the clinical urgency of recognizing genetic subtypes early and ensuring equitable access to disease-modifying therapies that can transform outcomes across the ATTR-CM spectrum.
Categoria
Cardiology
Commenta per primo questo video.

Prossimo